The Wishbone schreef:
Ja hoor hij is net klaar met zijn specht
Het ging over de plannen van de verdere producten
GTC is developing a recombinant human alpha-1 antitrypsin, a recombinant human albumin, a CD137 antibody to stimulate the immune system as a potential treatment for solid tumors, and a malaria vaccine.
groet
GTC BIOTHERAPEUTICS ANNOUNCES TIME CHANGE FOR WEBCAST OF CORPORATE PRESENTATION AT SG COWEN & CO. 6TH ANNUAL GLOBAL HEALTH CARE CONFERENCE
Framingham, Mass., November 4, 2005-- GTC Biotherapeutics, Inc. (Nasdaq: GTCB) (“GTC”) announced today a time change for the presentation to be given by Geoffrey Cox, Ph.D., Chairman and CEO of the Company, at the SG Cowen & Co. 6th Annual Global Health Care Conference. The presentation is now scheduled for 11:30 a.m. Central European Time (5:30 a.m. Eastern Time) on Thursday, November 10, 2005. The conference is being held at the Hilton Diagonal Mar, Barcelona, Spain.
The presentation will be webcast live and can be accessed by logging onto
www.gtc-bio.com. The replay can be accessed from this same website and will be available within 24 hours of the presentation.
GTC Biotherapeutics is a leader in the development, production, and commercialization of therapeutic proteins through transgenic animal technology. GTC's lead program is ATryn®, its recombinant form of human antithrombin. A Market Authorization Application is under review by the European Medicines Agency for the use of ATryn® in patients with a hereditary antithrombin deficiency. In addition to the ATryn® program, GTC is developing a recombinant human alpha-1 antitrypsin, a recombinant human albumin, a CD137 antibody to stimulate the immune system as a potential treatment for solid tumors, and a malaria vaccine. In its external programs, GTC's technology is used to develop transgenic production of its partners' proprietary products, including both large-volume protein therapeutics as well as products that are difficult to produce in significant quantities from conventional recombinant production systems. One of the external programs is in clinical trials with a transgenically produced product. Additional information is available on the GTC web site,
www.gtc-bio.com.